Gastroenterología y Hepatología (English Edition), Год журнала: 2024, Номер 47(10), С. 502263 - 502263
Опубликована: Ноя. 27, 2024
Язык: Английский
Cells, Год журнала: 2025, Номер 14(3), С. 221 - 221
Опубликована: Фев. 4, 2025
Cigarette smoke (CS), an intricate blend comprising over 4000 compounds, induces abnormal cellular reactions that harm multiple tissues. Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic (CLD), encompassing non-alcoholic (NAFL), steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Recently, the term NAFLD has been changed to metabolic dysfunction-associated steatotic (MASLD), NASH renamed (MASH). A multitude of experiments have confirmed association between CS incidence progression MASLD. However, specific signaling pathways involved need be updated with new scientific discoveries. exposure can disrupt lipid metabolism, induce inflammation apoptosis, stimulate fibrosis through promote Currently, there no officially approved efficacious pharmaceutical intervention in clinical practice. Therefore, lifestyle modifications emerged as primary therapeutic approach for managing Smoking cessation application series natural ingredients shown ameliorate pathological changes induced by CS, potentially serving effective decelerating MASLD development. This article aims elucidate which smoking promotes MASLD, while summarizing reversal factors identified recent studies, thereby offering novel insights future research on treatment
Язык: Английский
Процитировано
2
npj gut and liver., Год журнала: 2025, Номер 2(1)
Опубликована: Янв. 10, 2025
MetALD is a recently coined term that refers to systemic entity describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of risk factors synergistically increases the development steatohepatitis, fibrosis, hepatocellular carcinoma (HCC). Despite its increasing incidence, pathophysiological mechanisms triggering damage in remain unclear. This review aims summarize prevalence, pathophysiology MetALD, taking into account latest clinical translational aspects.
Язык: Английский
Процитировано
1
Digestive Diseases and Sciences, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
The new definition of steatotic liver disease (SLD), as a broader concept, was step forward in the increasing recognition substantial overlap between alcohol and cardiometabolic risk factors (CMRFs), continuum way. spectrum pathophysiological aspects, ranging from steatosis to fibrosis, has similarities MASLD ALD. Also, there is now considerable evidence that association metabolic dysfunction with increased consumption impacts on severe prognosis. MetALD class, recently proposed, shows clear differences prognosis when comparing ALD groups. However, room for improvement, such considering role previous intake, fluctuations over time, including binge drinking, refinement assessment, better understanding biomarkers. In summary, SLD no doubt significant but classification needs be dynamic adapting patients needing frequent reassessment. Furthermore, it brings opportunities research interaction CMRFs.
Язык: Английский
Процитировано
0
Liver International, Год журнала: 2025, Номер 45(5)
Опубликована: Апрель 3, 2025
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.
Язык: Английский
Процитировано
0
Therapeutic Advances in Gastroenterology, Год журнала: 2025, Номер 18
Опубликована: Апрель 1, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is an increasingly prevalent disorder. This study investigated the effect of smoking status on various clinical outcomes in MASLD and metabolic dysfunction alcohol-associated (MetALD). a retrospective cohort analysis utilizing data from UK Biobank (Application ID: 117214). Participants were categorized current, previous, or never smokers, analyzed using inverse probability treatment weighting to adjust for confounders. The primary all-cause mortality liver-related mortality. Secondary included incidence cirrhosis, hepatic decompensation, cardio-cerebrovascular diseases (CVD), hepatocellular carcinoma (HCC). Multivariate Cox proportional hazards models employed evaluate associations. Previous smokers had significantly lower hazard ratios (HRs) compared current all cohorts (HR: 0.33, 95% confidence interval (CI): 0.31-0.35, p < 0.001 No SLD cohort, HR: 0.43, CI: 0.41-0.44, 0.41, 0.38-0.45, MetALD cohort). showed incidences cirrhosis across cohorts, except MetALD. CVD smokers. In lowest decompensation HCC. no significant differences observed risk HCC between different statuses. Smoking related worse survival higher cohorts. Therefore, cessation prevention are crucial strategies reducing burden improving patient prognosis.
Язык: Английский
Процитировано
0
Expert Review of Endocrinology & Metabolism, Год журнала: 2025, Номер unknown, С. 1 - 12
Опубликована: Апрель 12, 2025
In 2023, metabolic dysfunction-associated steatotic liver disease (MASLD) was introduced following fatty (MAFLD). Both aim to address the limitations of nonalcoholic (NAFLD). This review analyzes similarities and differences between MAFLD MASLD, focusing on their impacts epidemiology, diagnosis, stigma, related diseases. Current evidence suggests that criteria effectively identify individuals at higher risk through a good balance sensitivity specificity. Moreover, is more generalizable term easily understood globally. The transition from NAFLD MASLD marks significant advance in understanding within hepatology. identifies homogeneous cohort patients with due dysfunction provides valuable framework for holistic, patient-centered management strategies consider various contributing factors improve health outcomes.
Язык: Английский
Процитировано
0
Metabolism, Год журнала: 2024, Номер 163, С. 156101 - 156101
Опубликована: Дек. 10, 2024
Язык: Английский
Процитировано
1
Gastroenterología y Hepatología (English Edition), Год журнала: 2024, Номер 47(10), С. 502263 - 502263
Опубликована: Ноя. 27, 2024
Язык: Английский
Процитировано
0